BCRX · NASDAQ
BioCryst Pharmaceuticals, Inc.
$8.46 -0.06 (-0.70%)
Company overview
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names, and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $2.2B
- Employees
- 580
- Headquarters
- Durham, NC
- Website
- biocryst.com
- CEO
- Charles K. Gayer
- Listed
- March 4, 1994
- P/E
- -4.89
- Dividend yield
- 0.00%
Company financials
- Revenue
- $886M
- Gross profit
- $167M
- Operating income
- -$382M
- EBITDA
- -$375M
- Net income
- -$458M
- EPS
- -$1.73
- Total assets
- $465M
- Total debt
- $858M
- Gross margin
- 18.89%
- Net margin
- -51.71%
- Earnings yield
- -20.43%
No geographic segmentation.
Showing FY 2025
BCRX
1D
NASDAQ
O8.47H8.56L8.44C8.52+0.15 (+1.79%)Vol616.42K